Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the study content and navigation with an error message and a Home link.SummaryDifference19%

- Check14 days agoChange DetectedThe page now adds 'Type 2 diabetes' under related topics and includes a MedlinePlus Genetics entry in related topics. These additions provide quick access to broader background information about the condition and genetics related to the study area.SummaryDifference0.2%

- Check21 days agoChange DetectedThe page no longer displays Type 2 diabetes and the MedlinePlus Genetics related topics section. This reduces disease-specific context and associated background resources.SummaryDifference0.2%

- Check28 days agoChange DetectedThe page adds new related topics, including Type 2 diabetes and a MedlinePlus Genetics entry. The revision label updates from v3.6.5 to v3.6.6 to reflect a new version.SummaryDifference0.2%

- Check43 days agoChange DetectedRemoved the related topics entries for Type 2 diabetes and MedlinePlus Genetics from the page. This change affects discoverability but not the core study details.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page revision label changed from v3.6.4 to v3.6.5, indicating a software update. No trial details or visible content were altered.SummaryDifference0.1%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.